Table 1:

Main features of RANO 2.0

RANO 2.0 overview
Baseline
 Newly diagnosed tumorsPost-RT scan
 Recurrent tumorsPre-Tx scan
Tumor components to evaluate
 CE tissueIn all tumors
 Non-CE tissue- In non-CE tumors- In “mixed” tumors with CE + non-CE components- Optional in CE tumors for trials using agents that affectvascular permeability (e.g., antiangiogenic)
Measurement technique
 Sum of bidimensional products or volumetric segmentations
Thresholds applied to target lesions
 CRcomplete disappearance of all lesions
 PD≥ +25% in sum of bidimensional productsor ≥ +40% in volume
 PR≤ –50% in sum of bidimensional productsor ≤ –65% in volume
 MRa≤ –25% and > –50% in sum of bidimensional productsor ≤ –40% and > –65% in volume
 SDcriteria for CR / PR / MR / PD are not met
Confirmatory scans (performed after >4 weeks)
 For PD- Mandatory for CE tumors ≤12 weeks from RT- Optional for CE tumors >12 weeks from RT (recommended for agentsb highly associated with PsP) - Unnecessary for non-CE tumors
 For CR/PRMandatory for all tumors at all timepoints

  • Note:—CE indicates contrast-enhancing; CR, complete response; MR, minor response; PD, progressive disease; PsP, pseudoprogression; PR, partial response; RT, radiotherapy; SD, stable disease; Tx, treatment.

  • ↵a MR only applies to non-CE disease.

  • ↵b e.g., immunotherapies.